2225 East Bayshore Road
Palo Alto, CA 94303
Impiegati a tempo pieno:
|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Gergely Toth||Founder, CEO, Pres & Director||157k||N/D||1974|
|Dr. Thomas Roger Sawyer M.B.A., Ph.D.||CFO & Director||109k||N/D||1970|
|Dr. Balász Herberth||Head of Cell Biology & In Vitro Pharmacology||N/D||N/D||N/D|
Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.
L'ISS Governance QualityScore di Cantabio Pharmaceuticals, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.